ABT vs ZBH Stock Comparison: AI Score, Valuation, Performance and Upside
Abbott Laboratories and Zimmer Biomet both operate in medical devices, but Abbott offers a diversified healthcare business spanning devices, diagnostics, nutrition, and pharmaceuticals including a fast-growing glucose monitoring franchise, while Zimmer Biomet specializes specifically in orthopedic implants and robotic-assisted joint replacement surgery.
Abbott Laboratories offers diversified healthcare exposure anchored by a fast-growing continuous glucose monitoring franchise, while Zimmer Biomet offers focused exposure to orthopedic implant demand and robotic surgery adoption. Consider whether you prefer Abbott's diversification or Zimmer Biomet's specialized orthopedic focus.
ZBH holds the edge across 3 of 5 key metrics in this comparison. ZBH leads on both 1-year return (-3.63%) and forward P/E quality (11.13x vs 16.81x for ABT), a relatively favorable combination of momentum and valuation. On fundamentals, ABT is growing revenue faster (13.00%), while ZBH maintains the higher operating margin (17.96%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for ABT (+17.96%) than for ZBH (+6.60%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want diversified healthcare exposure across devices, diagnostics, nutrition, and pharmaceuticals
- Believe the continuous glucose monitoring franchise offers a strong long-term growth driver
- Value strong global brand recognition and distribution across developed and emerging markets
- Prefer reduced dependence on any single healthcare business segment
- Want focused exposure to orthopedic implant demand tied to an aging population
- Believe the robotic-assisted surgery platform offers meaningful differentiation and growth
- Value an established leadership position in knee and hip replacement systems
- Are comfortable with exposure concentrated in a single medical device category
| Metric | ABT | ZBH |
|---|---|---|
| AI scorei | 51.3 | 37.8 |
| AI ranki | #437 | #2407 |
| Latest closei | $104.57 | $97.47 |
| 1M returni | +3.59% | +6.71% |
| 3M returni | -0.98% | +2.64% |
| 6M returni | +15.18% | +18.25% |
| 1Y returni | -17.41% | -3.63% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | ABT | ZBH |
|---|---|---|
| 1Y ago | $8.4K (-16.0%) started 2025-10-29 | $9.78K (-2.2%) started 2025-10-29 |
| 5Y ago | $9.28K (-7.2%) started 2021-11-01 | $7.29K (-27.1%) started 2021-11-01 |
| 10Y ago | $36.74K (+267.4%) started 2016-10-31 | $10.92K (+9.2%) started 2016-10-31 |
Hypothetical — past performance does not guarantee future results.
| Metric | ABT | ZBH |
|---|---|---|
| Market capi | $176.41B | $19.25B |
| Trailing P/Ei | 32.99 | 24.49 |
| Forward P/Ei | 16.81 | 11.13 |
| Price/Salesi | 5.49 | 2.37 |
| EV/Revenuei | 4.38 | 3.10 |
| Analyst targeti | $120.26 | $107.57 |
| Target upsidei | +17.96% | +6.60% |
| Metric | ABT | ZBH |
|---|---|---|
| Revenue growthi | 13.00% | 4.80% |
| Earnings growthi | -47.50% | 33.80% |
| EPS growthi | -47.50% | +33.80% |
| FCF margini | +15.48% | +12.82% |
| Operating margini | 14.71% | 17.96% |
| Profit margini | 11.65% | 9.48% |
| ROIC proxyi | 10.58% | 6.41% |
| Return on equityi | 10.58% | 6.41% |
| Dividend yieldi | 2.47% | 0.95% |
| Payout ratioi | 78.71% | 23.30% |
| Dividend growth streaki | No increase yet | No increase yet |
| Betai | 0.59 | 0.46 |
| Debt/equityi | 63.21 | 60.17 |
| Current ratioi | 1.38 | 1.69 |
| Quick ratioi | 0.80 | 0.74 |
Over the past year, ABT and ZBH have moved weakly in the same direction (correlation of 0.38), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | ABT | ZBH |
|---|---|---|---|
| 1Y | Growthi | -15.96% | -2.25% |
| CAGRi | -15.98% | -2.25% | |
| Volatilityi | 27.29% | 32.67% | |
| Sharpe ratioi | -0.67 | -0.04 | |
| Sortino ratioi | -0.93 | -0.05 | |
| Max drawdowni | 36.78% | 22.87% | |
| Current drawdowni | 19.92% | 5.53% | |
| Avg drawdowni | 18.07% | 11.02% | |
| Ulcer Indexi | 20.74% | 12.05% | |
| Max daily dropi | 10.04% | 15.15% | |
| Max wkly dropi | 13.11% | 14.23% | |
| 5Y | Growthi | -13.36% | -29.14% |
| CAGRi | -2.83% | -6.67% | |
| Volatilityi | 23.11% | 27.18% | |
| Sharpe ratioi | -0.20 | -0.28 | |
| Sortino ratioi | -0.28 | -0.38 | |
| Max drawdowni | 40.85% | 44.52% | |
| Current drawdowni | 25.08% | 32.05% | |
| Avg drawdowni | 18.10% | 23.23% | |
| Ulcer Indexi | 20.23% | 25.25% | |
| Max daily dropi | 10.04% | 15.15% | |
| Max wkly dropi | 13.11% | 14.23% | |
| 10Y | Growthi | +211.04% | +1.89% |
| CAGRi | +12.02% | +0.19% | |
| Volatilityi | 24.00% | 28.47% | |
| Sharpe ratioi | 0.41 | -0.01 | |
| Sortino ratioi | 0.58 | -0.01 | |
| Max drawdowni | 40.85% | 52.63% | |
| Current drawdowni | 25.08% | 41.98% | |
| Avg drawdowni | 10.97% | 22.13% | |
| Ulcer Indexi | 14.78% | 26.83% | |
| Max daily dropi | 10.04% | 15.15% | |
| Max wkly dropi | 16.72% | 27.48% |
| Category | ABT | ZBH |
|---|---|---|
| Company | Abbott Laboratories | Zimmer Biomet Holdings, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
| Core business | A diversified healthcare company with businesses spanning medical devices, diagnostics, nutrition, and established pharmaceuticals, including a fast-growing continuous glucose monitoring franchise for diabetes management. | A medical device company specializing in orthopedic implants and surgical products, including knee and hip replacement systems, alongside a growing robotic-assisted surgery platform for joint replacement procedures. |
| Investor focus | Continuous glucose monitoring franchise growth and market penetration, diagnostics segment stability, and overall diversification benefits across its medical device, nutrition, and pharmaceutical businesses. | Orthopedic implant procedure volume trends, robotic-assisted surgery platform adoption, and overall competitive positioning within the joint replacement device market. |
- Fast-growing continuous glucose monitoring franchise provides exposure to rising diabetes prevalence and expanding non-diabetic use cases
- Diversification across medical devices, diagnostics, nutrition, and pharmaceuticals reduces dependence on any single business segment
- Strong global brand recognition and distribution support product adoption across both developed and emerging markets
- Established leadership position in knee and hip replacement implants built on decades of orthopedic surgery expertise
- Growing robotic-assisted surgery platform provides a differentiated technology offering within joint replacement procedures
- Aging population demographics support long-term demand growth for orthopedic implant procedures
- Continuous glucose monitoring market faces increasing competition from other established medical device makers
- Diagnostics segment growth can be uneven depending on testing volumes and public health conditions
- Broad business diversification means overall growth reflects a blend of faster and slower-growing segments
- Orthopedic implant procedure volumes can be sensitive to hospital staffing, scheduling, and elective procedure trends
- Faces intense competition from other established orthopedic device makers in knee and hip replacement systems
- Robotic-assisted surgery platform must continue gaining adoption to justify its role as a differentiating growth driver
Compare more than two at a time
This page is a fixed writeup on ABT and ZBH. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside ABT and ZBH, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.